Vizient has ranked Rush University Medical Center #1 for quality among the nation’s most prestigious academic medical centers. Learn more.

Excellence is just the beginning.


French German Italian Portuguese Russian

Hepatoblastoma Treatment Study

Clinical Trial Title: 
Treatment of children with all stages of hepatoblastoma with temsirolimus (IND#122782, NSC#683864) added to high risk stratum treatment.
Clinical Trial Protocol ID: 
Clinical Trial Investigator Name: 
Mary Lou Schmidt, MD
Clinical Trial Protocol Description: 

A risk-based treatment approach will maintain or improve event-free survival (EFS), decrease acute and long-term chemotherapy toxicity, and identify new agents in the treatment of children with hepatoblastoma.

Clinical Trial Eligibility Criteria: 

In order to participate you must meet the following criteria:

  • Are less than 21 years of age at the time of diagnosis.
  • Have been newly diagnosed with histologically-proven hepatoblastoma.

This is a partial list of elgibility requirements.

Clinical Trial Area: 
Pediatric Cancers and Blood Disorders
Contact Phone: 
(312) 355-0741
Contact Name: 
Nitin Sane